secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001493152-26-013290
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND
--------------------------------------------------------------------------------

- Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.
- Cash $4.7M at Dec 31; raised $12.2M in gross proceeds during FY 2025; subsequently raised $1.5M (Jan 2026) and $1.45M (Feb 2026).
- EB-003 showed positive preclinical results in chronic depression and PTSD models; preparing IND submission to FDA for first-in-human trial.
- PGR petition by Gilgamesh/AbbVie against Enveric patent withdrawn; patent covers bretisilocin (GM-2505) acquired by AbbVie for $1.2B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/0001493152-26-013290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer